Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Acute Lymphoblastic Leukemia Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023


 

Available formats:    

StumbleUponEmail

Increase in the incidence of acute lymphoblastic leukemia, rise in the R&D activities for the innovation of novel therapies, growing in healthcare expenditure, and advancement in molecular biology and pharmacology for development of novel drugs are anticipated to fuel the acute lymphoblastic leukemia treatment market. In addition, rise in awareness programs for acute lymphoblastic leukemia treatment, and increase in healthcare expenditure are expected propel the growth of acute lymphoblastic leukemia treatment market over the forecast period. However, stringent regulatory policies, high cost of treatment, adverse effects associated with the treatment, and complications with chemotherapy are expected to hinder the growth of acute lymphoblastic leukemia treatment market over the forecast period.

 

Global Acute Lymphoblastic Leukemia Treatment Market:

 

Acute lymphoblastic leukemia or acute lymphocytic leukemia is a type of leukemia occurs due to the accumulation and overproduction of cancerous white blood cells known as lymphoblasts in the bone marrow. Acute lymphoblastic leukemia may spread to other body organs such as liver, spleen, lymph nodes, and central nervous system among others. Acute lymphoblastic leukemia is most commonly occurs in children and sometimes in children with 2-5 years of age and rarely occurs in old age population. Common signs and symptoms associated with the acute lymphoblastic leukemia include fatigue, fever, frequent infections, bruising, weight loss, joint pains, and swollen lymph glands among others. It can be diagnosed by bone marrow test, blood test, ultrasound, MRI, and CT scans among others.

 

Acute lymphoblastic leukemia treatment market is segmented on the basis of disease type, treatment type, route of administration, and end users

 

Based on the disease type, acute lymphoblastic leukemia treatment market is segmented into the following:

  • Acute B-lymphoblastic Leukemia
  • Acute T-lymphoblastic Leukemia
  • Others

 

Based on the treatment type, acute lymphoblastic leukemia treatment market is segmented into the following:

  • Chemotherapy
    • Corticosteroids
    • Colony-stimulating Factors
    • Tyrosine Kinase Inhibitors
    • Others
  • Immunotherapy
  • Others

 

Based on the route of administration, acute lymphoblastic leukemia treatment market is segmented into the following:

  • Oral
  • Parenteral

 

Based on the distribution channel, acute lymphoblastic leukemia treatment market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

 

Acute lymphoblastic leukemia treatment market is growing at lucrative rate owing to increase in the prevalence of acute lymphoblastic leukemia prevalence in developing countries due to genetic factors. The rise in R&D activities for the innovation of newer chemotherapy and immunotherapy molecules is anticipated to fuel the acute lymphoblastic leukemia treatment market. Moreover, acquisitions and mergers, collaborations, and product launchings are the key strategies followed by the companies for dominating the acute lymphoblastic leukemia treatment market. For instance, In April 2014, Rare Disease Therapeutics, Inc. received FDA approval for Purixan oral suspension, used in the treatment of acute lymphoblastic leukemia. Moreover, in September 2015, Baxter International Inc. acquired Oncaspar product portfolio from the Sigma-Tau Finanziaria S.p.A. for strengthening its acute lymphoblastic leukemia portfolio.

 

 

Geographically, acute lymphoblastic leukemia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has a significant growth which is attributed to increase in the prevalence of acute lymphoblastic leukemia (according to estimation of American Cancer Society about 6,590 new cases and 1,430 deaths are observed in U.S.), rise in R&D for innovation of new drugs, and various drugs approved by FDA are fuelling the acute lymphoblastic leukemia treatment market in the region. In Europe, rise in prevalence of acute lymphoblastic leukemia majorly in Russia, Norway, and U.K (according to Cancer Research U.K. 2014, about 758 new cases were observed in U.K.), rise in awareness about the disease treatment, and increase in healthcare expenditure are the factors boosting the acute lymphoblastic leukemia treatment market. However, Asia Pacific has a lucrative growth which is attributed to high prevalence of the disease majorly in Australia.

 

 

Some of the players in acute lymphoblastic leukemia treatment market are Pfizer, Inc. (U.S.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Genzyme Corporation (U.S.). Talon Therapeutic, Inc. (U.S.), Erytech Pharma (France), Baxter International Inc. (U.S.), Novartis AG (Switzerland), and Rare Disease Therapeutics, Inc. (U.S.) to name a few.

 

  • In August 2017, Pfizer, Inc. has received FDA approval for Besponsa (inotuzumab ozogamycin) used in the treatment of refractory B-cell precursor acute lymphoblastic leukemia
  • In August 2017, Novartis AG received FDA approval for Kymriah suspension for intravenous infusion used in the treatment of refractory B-cell precursor acute lymphoblastic leukemia in patients up to 25 years of age

 

 

Report Outline:

  • The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Pfizer, Inc. (U.S.)
  • Sigma-Tau Pharmaceuticals, Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Genzyme Corporation (U.S.)
  • Talon Therapeutic, Inc. (U.S.)
  • Erytech Pharma (France)
  • Baxter International Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Rare Disease Therapeutics, Inc. (U.S.)

1. Executive Summary

 

2. Global Acute Lymphoblastic Leukemia Treatment Market Introduction

 

2.1. Global Acute Lymphoblastic Leukemia Treatment Market – Taxonomy

2.2. Global Acute Lymphoblastic Leukemia Treatment Market –Definitions

2.2.1. Disease Type

2.2.2. Treatment Type

2.2.3. Rout of Administration

2.2.4. Distribution Channel

 

3. Global Acute Lymphoblastic Leukemia Treatment Market Dynamics

 

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Acute Lymphoblastic Leukemia Treatment Market Dynamic Factors – Impact Analysis

3.6. Global Acute Lymphoblastic Leukemia Treatment Market – Competition Landscape

3.7. Epidemiology

 

4. Global Acute Lymphoblastic Leukemia Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024

 

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market OpportunityAnalysis

 

5. Global Acute Lymphoblastic Leukemia Treatment Market, By Disease Type, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1. Acute B-lymphoblastic Leukemia

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Acute T-lymphoblastic Leukemia

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

 

5.3. Others

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

 

6. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Treatment Type,2013 – 2017 and Forecast, 2017 – 2024

 

6.1. Chemotherapy

6.1.1. Corticosteroids

6.1.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.1.3. Market Opportunity Analysis

6.1.2. Colony-stimulating Factors

6.1.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.2.3. Market Opportunity Analysis

6.1.3. Tyrosine Kinase Inhibitors

6.1.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3.3. Market Opportunity Analysis

6.1.4. Others

6.1.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.4.3. Market Opportunity Analysis

 

6.2. Immunotherapy

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

 

6.3. Others

6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

 

7. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

7.1. Oral

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

 

7.2. Parenteral

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

 

8. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

8.1. Hospital Pharmacies

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

 

8.2. Retail Pharmacies

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

 

8.3. Online Pharmacies Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

 

9. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

9.1. North America

9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.1.3. Market Opportunity Analysis

 

9.2. Europe

9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.2.3. Market Opportunity Analysis

 

9.3. Asia-Pacific

9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.3.3. Market Opportunity Analysis

 

9.4. Latin America

9.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.4.3. Market Opportunity Analysis

 

9.5. Middle East and Africa

9.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.5.3. Market Opportunity Analysis

 

9.6. Global Acute Lymphoblastic Leukemia Treatment Market – Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2018 – 2024

 

10. North America Acute Lymphoblastic Leukemia Treatment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

10.1. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Acute B-lymphoblastic Leukemia

10.1.2. Acute T-lymphoblastic Leukemia

10.1.3. Others

 

10.2. Treatment Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Chemotherapy

10.2.1.1. Corticosteroids

10.2.1.2. Colony-stimulating Factors

10.2.1.3. Tyrosine Kinase Inhibitors

10.2.1.4. Others

10.2.2. Immunotherapy

10.2.3. Others

 

10.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Oral

10.3.2. Parenteral

 

10.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Online Pharmacies

 

10.5. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.5.1. U.S.

10.5.2. Canada

 

10.6. North America Acute Lymphoblastic Leukemia Treatment Market – Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024

10.7. North America Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends

 

11. Europe Acute Lymphoblastic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

11.1. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Acute B-lymphoblastic Leukemia

11.1.2. Acute T-lymphoblastic Leukemia

11.1.3. Others

 

11.2. Treatment Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Chemotherapy

11.2.1.1. Corticosteroids

11.2.1.2. Colony-stimulating Factors

11.2.1.3. Tyrosine Kinase Inhibitors

11.2.1.4. Others

11.2.2. Immunotherapy

11.2.3. Others

 

11.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Oral

11.3.2. Parenteral

 

11.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Online Pharmacies

 

11.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.5.1. Germany

11.5.2. UK

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Russia

11.5.7. Poland

11.5.8. Rest of Europe

 

11.6. Europe Acute Lymphoblastic Leukemia Treatment Market – Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2018 – 2024

 

11.7. Europe Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends

 

12. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

12.1. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Acute B-lymphoblastic Leukemia

12.1.2. Acute T-lymphoblastic Leukemia

12.1.3. Others

 

12.2. Treatment Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Chemotherapy

12.2.1.1. Corticosteroids

12.2.1.2. Colony-stimulating Factors

12.2.1.3. Tyrosine Kinase Inhibitors

12.2.1.4. Others

12.2.2. Immunotherapy

12.2.3. Others

 

12.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Oral

12.3.2. Parenteral

 

12.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

 

12.5. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

12.5.1. Japan

12.5.2. China

12.5.3. India

12.5.4. ASEAN

12.5.5. Australia & New Zealand

12.5.6. Rest of Asia-Pacific

 

12.6. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market – Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024

 

12.7. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends

 

13. Latin America Acute Lymphoblastic Leukemia Treatment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

13.1. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Acute B-lymphoblastic Leukemia

13.1.2. Acute T-lymphoblastic Leukemia

13.1.3. Others

 

13.2. Treatment Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Chemotherapy

13.2.1.1. Corticosteroids

13.2.1.2. Colony-stimulating Factors

13.2.1.3. Tyrosine Kinase Inhibitors

13.2.1.4. Others

13.2.2. Immunotherapy

13.2.3. Others

 

13.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Oral

13.3.2. Parenteral

 

13.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

 

13.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Argentina

13.5.4. Venezuela

13.5.5. Rest of Latin America

 

13.6. Latin America Acute Lymphoblastic Leukemia Treatment Market – Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2018 – 2024

 

13.7. Latin America Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends

 

14. Middle East and Africa Acute Lymphoblastic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

14.1. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

14.1.1. Acute B-lymphoblastic Leukemia

14.1.2. Acute T-lymphoblastic Leukemia

14.1.3. Others

 

14.2. Treatment Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.2.1. Chemotherapy

14.2.1.1. Corticosteroids

14.2.1.2. Colony-stimulating Factors

14.2.1.3. Tyrosine Kinase Inhibitors

14.2.1.4. Others

14.2.2. Immunotherapy

14.2.3. Others

 

14.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.3.1. Oral

14.3.2. Parenteral

 

14.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Online Pharmacies

 

14.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

14.5.1. Gulf Cooperation Council (GCC) Countries

14.5.2. Israel

14.5.3. South Africa

14.5.4. Rest of MEA

 

14.6. MEA Acute Lymphoblastic Leukemia Treatment Market – Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024

14.7. MEA Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends

 

15. Competition Landscape

 

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

15.2.1. Pfizer, Inc. (U.S.)

15.2.2. Sigma-Tau Pharmaceuticals, Inc. (U.S.)

15.2.3. GlaxoSmithKline plc (U.K.)

15.2.4. Genzyme Corporation (U.S.)

15.2.5. Talon Therapeutic, Inc. (U.S.)

15.2.6. Erytech Pharma (France)

15.2.7. Baxter International Inc. (U.S.)

15.2.8. Novartis AG (Switzerland)

15.2.9. Rare Disease Therapeutics, Inc. (U.S.)

 

16. Research Methodology

17. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553